Lazard Asset Management
VRDN icon

Lazard Asset Management’s Viridian Therapeutics VRDN Stock Holding History

Lazard Asset Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$98.9K Buy
+5,386
New +$86.8K ﹤0.01% 1757

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Lazard Asset Management's VRDN Position: Q2 2026 in Review

Lazard Asset Management opened a new position in Viridian Therapeutics (VRDN) in Q2 2026: 5,386 shares worth $98.9K. The stake represents ﹤0.01% of the portfolio and ranks #1757 among its holdings.

212 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Lazard Asset Management held 5,386 shares of Viridian Therapeutics worth $98.9K as of Q2 2026.
  • Viridian Therapeutics was a new Lazard Asset Management position in Q2 2026.
  • Viridian Therapeutics made up ﹤0.01% of Lazard Asset Management's portfolio in Q2 2026, its #1757 holding.
  • 212 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.